BIOPOR Bioporto A/S

Managers’ transactions

Managers’ transactions

January 21, 2021

Announcement no. 1

Managers’ transactions

BioPorto has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely related with them. BioPorto has been notified that the transaction is carried out for the purpose of settling tax liabilities arising out of returns on BioPorto shares held as pension scheme assets.

1. Details of the person discharging managerial responsibilities/person closely associated 
a) NameThomas Magnussen
2. Reason for the notification 
a) Position/statusChairman of the Board of Directors of BioPorto A/S
b) Initial notification/amendmentInitial notification
3. Details of the issuer 
a) NameBioPorto A/S
b) LEI5299004SWFL5JAN4W830
4. Details of the transaction(s) 
a) Description of the financial instrument, type



of instrument







Identification code
Shares



 





ISIN code DKDK0011048619
b) Nature of the transactionShare sale
c) Price(s) and volume(s)Price: DKK 6.14, Volume: 40,000
d) Aggregated information



  • Aggregated volume



  • Aggregated price
N/A
e) Date of the transaction2021-01-18
f) Place of the transactionNasdaq Copenhagen A/S, XCSE

For further information, please contact:

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment



EN
21/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

Opdatering af forretningsstrategi – Strategien "Forward", aspirationer...

Opdatering af forretningsstrategi – Strategien "Forward", aspirationer frem mod 2028 og finansieringsbehov 4. november, 2025Meddelelse nr. 23 Opdatering af forretningsstrategi – Strategien "Forward", aspirationer frem mod 2028 og finansieringsbehov KØBENHAVN, DANMARK, 4. november, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” eller “Selskabet”) (CPH:BIOPOR), annoncerede i dag en opdatering af forretningsstrategien, aspirationer frem mod 2028 og den nødvendige finansiering til at understøtte forretningen indtil cash flow er positivt i 2. halvår af 2027. CEO Carsten Buhl præsenterer den...

 PRESS RELEASE

Business Strategy Update – the “Forward” Strategic Direction, Aspirati...

Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs November 4, 2025Announcement no. 23 Business Strategy Update – the “Forward” Strategic Direction, Aspirations towards 2028 and Funding Needs Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced a business strategy update, aspirations towards 2028 and funding needed to support the business until cash flow positive in the second half of 2027. CEO Carsten Buhl will present the Business Strategy Update on an inve...

 PRESS RELEASE

Forudgående offentliggørelse af de finansielle nøgletal for 3. kvartal...

Forudgående offentliggørelse af de finansielle nøgletal for 3. kvartal 2025 og reviderede forventninger til regnskabsåret 2025 4. november, 2025                                                Meddelelse nr. 22 Forudgående offentliggørelse af de finansielle nøgletal for 3. kvartal 2025 og reviderede forventninger til regnskabsåret 2025 KØBENHAVN, DANMARK, 4. november, 2025 – BioPorto A/S (”BioPorto” eller ”Selskabet”) (CPH:BIOPOR), annoncerede i dag en forudgående offentliggørelse af de finansielle nøgletal for tredje kvartal 2025 og reviderede forventninger til regnskabsåret 2025. Fina...

 PRESS RELEASE

Pre-announcement of the Key Financial Results for Third Quarter 2025 a...

Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 November 4, 2025                                                Announcement no. 22 Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025  Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today pre-announced the key financial results for the third quarter of 2025 and revised guidance for 2025. Key Financial Results for Q3 2025 reflect Continued NGAL Sales Growth Revenue in the t...

 PRESS RELEASE

Statusopdatering på BioPortos kliniske studie for voksne

Statusopdatering på BioPortos kliniske studie for voksne 4. november, 2025Meddelelse nr. 21 Statusopdatering på BioPortos kliniske studie for voksne KØBENHAVN, DANMARK, 4. november – BioPorto A/S (BioPorto eller Selskabet) (CPH:BIOPOR), annoncerede i dag en statusopdatering på sit igangværende kliniske studie til risikovurdering af akut nyreskade (AKI) hos voksne patienter. Ultimo oktober 2025, afsluttede BioPorto indrulleringen af patienter til sit kliniske cut-off-studie. Selskabet er i øjeblikket ved at indsamle data fra cut-off studiet, og denne proces tager længere tid end oprind...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch